BioSpace News Archive

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled ‘BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreatic Cancer: The COMBAT Trial,’ has been published in the peer-reviewed journal Nature Medicine

Findings From Qualitative Patient Substudy Evaluating Health-Related Quality of Life in Patients With Schizophrenia and Treatment Satisfaction, Including Treatment with ALKS 3831, to be Presented

New MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program

Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies

vTv Therapeutics Inc. announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Association’s 80th Scientific Sessions, which is being held virtually, June 12–16, 2020.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in two upcoming investor conferences.

Crescita Therapeutics Inc. and, a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development and manufacturing capabilities, reported its financial results for the first quarter ended March 31, 2020.

Novartis announced that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology.

ISTURISA® (osilodrostat) Is Now Exclusively Available Through AnovoRx Specialty Pharmacy. In an Effort to Increase Patient Access to ISTURISA, Recordati Rare Diseases Has Established the R.A.R.E. Patient Support Program. LEBANON, N.J.--( BUSINESS WIRE )-- Recordati Rare Diseases Inc. announced today the full availability of ISTURISA® (osilodrostat) for sale and distribution in the United States. ISTURISA was approved by the US Food and Drug Administra

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the Jefferies Virtual Healthcare Conference. The presentation will take place on Wednesday, June 3, 2020, at 1:30 PM